Epidemiology of atopic dermatitis in adults

There are gaps in our knowledge of the prevalence of adult atopic dermatitis (AD). To estimate the prevalence of AD in adults and by disease severity. Methods: This international, cross-sectional, web-based survey was performed in the United States, Canada, France, Germany, Italy, Spain, United King...

Descripción completa

Detalles Bibliográficos
Autores: Barbarot, Sebastien|||0000-0002-6629-9100, Auziere, Sébastien, Gadkari, Abhijit, Girolomoni, Giampiero|||0000-0001-8548-0493, Puig Sanz, Lluís|||0000-0001-6083-0952, Simpson, Eric L.|||0000-0002-8793-7087, Margolis, David J., de Bruin-Weller, Marjolein|||0000-0002-1249-6993, Eckert, Laurent|||0000-0002-7801-4125
Tipo de recurso: artículo
Fecha de publicación:2018
País:España
Institución:Universitat Autònoma de Barcelona
Repositorio:Dipòsit Digital de Documents de la UAB
Idioma:inglés
OAI Identifier:oai:ddd.uab.cat:286908
Acceso en línea:https://ddd.uab.cat/record/286908
https://dx.doi.org/urn:doi:10.1111/all.13401
Access Level:acceso abierto
Palabra clave:Atopic dermatitis
Epidemiology
Prevalence
Severity
Descripción
Sumario:There are gaps in our knowledge of the prevalence of adult atopic dermatitis (AD). To estimate the prevalence of AD in adults and by disease severity. Methods: This international, cross-sectional, web-based survey was performed in the United States, Canada, France, Germany, Italy, Spain, United Kingdom, and Japan. Adult members of online respondent panels were sent a questionnaire for AD identification and severity assessment; demographic quotas ensured population representativeness for each country. A diagnosis of AD required subjects to be positive on the modified UK Working Party/ISAAC criteria and self-report of ever having an AD diagnosis by a physician. The proportion of subjects with AD who reported being treated for their condition was determined and also used to estimate prevalence. Severity scales were Patient-Oriented SCORAD, Patient-Orientated Eczema Measure, and Patient Global Assessment. Among participants by region, the point prevalence of adult AD in the overall/treated populations was 4.9%/3.9% in the US, 3.5%/2.6% in Canada, 4.4%/3.5% in the EU, and 2.1%/1.5% in Japan. The prevalence was generally lower for males vs females, and decreased with age. Regional variability was observed within countries. Severity varied by scale and region; however, regardless of the scale or region, proportion of subjects reporting severe disease was lower than mild or moderate disease. Prevalence of adult AD ranged from 2.1% to 4.9% across countries. Severe AD represented a small proportion of the overall AD population regardless of measure or region.